

## Synthetic ligustrazine based cyclohexanone and oxime analogs as Anti-*Trypanosoma* and Anti-*Leishmanial* agents

Abdulsalam A. M. Alkhaldi<sup>1</sup>, Harry P. de Koning<sup>2</sup>, Syed Nasir Abbas Bukhari<sup>3\*</sup>

<sup>1</sup>Biology department, College of Science, Jouf University, Sakaka, Aljouf 2014, Saudi Arabia,

<sup>2</sup>Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8TA, UK, <sup>3</sup>Department of Pharmaceutical Chemistry, College of Pharmacy, Jouf University, Sakaka, Aljouf 2014, Saudi Arabia

In the present study a series of 34 synthetic ligustrazine-containing  $\alpha$ ,  $\beta$ -Unsaturated carbonyl-based compounds and oximes, recognized as anticancer compounds were assessed against protozoa of the *Trypanosoma* and *Leishmania* species. Ligustrazine, chemically known as tetramethylpyrazine (TMP), was selected as the core moiety for the synthesis of  $\alpha$ ,  $\beta$ -Unsaturated carbonyl-based compounds and these compounds were selected as precursors for the synthesis of new oximes. Some derivatives, including **5f** and **6i**, showed multiple activities against all tested strains. In particular compounds **5f** and **8o** are the most potent and they are, therefore, potential candidates for trypanosomiasis and leishmaniasis.

**Keywords:** Protozoan parasites. Sleeping sickness.  $\alpha$ , $\beta$ -Unsaturated carbonyl-based compounds; toxicity. Organic synthesis.

### INTRODUCTION

Leishmaniasis and trypanosomiasis are among the most neglected diseases of animals and humans caused by kinetoplastid protozoa, such as genera *Leishmania* and *Trypanosoma* (Barrett, 2000; Olliaro *et al.*, 2002). Sleeping sickness, commonly called human African trypanosomiasis (HAT), is a medical condition caused by protozoa of the genus *Trypanosoma* (Barrett *et al.*, 2003; Büscher *et al.*, 2017). Sleeping sickness is spread by the tsetse fly, and caused by two subspecies of *Trypanosoma brucei brucei*, *T. b. gambiense* and *T. b. rhodesiense* (Büscher *et al.*, 2017). There are two stages of disease. Stage 1, commonly called hemolympathic stage, involves the proliferation of the parasite in the blood and lymph. In Stage 2, referred to as the meningoencephalitic stage, the infection has crossed the blood brain barrier and reached the CNS (Bisser *et*

*al.*, 2006; Blum *et al.*, 2006). Cognitive dysfunction, sleep disturbance, coma and death are the signs and symptoms of late-stage HAT. Except for diagnosis and treatment in the early stage, drugs should be able to cross the blood-brain barrier to have a therapeutic effect. The non-availability of a vaccine for African trypanosomiasis (La Greca, Magez, 2011) ensures that chemotherapy remains the only therapeutic option and requires a drive to discover and develop novel chemical entities into operational medicines for HAT and various other neglected diseases. Although the WHO suggests a decrease in HAT incidence over the last decade, it will still be necessary to develop novel and active agents to combat the disease (WHO Report. 2015).

Leishmaniasis is a disease caused by *Leishmania*, a genus of protozoan parasites. The reservoir hosts of the majority of *Leishmania* species are canids and rodents from which parasites are transferred to humans via phlebotomine sand flies; transmission from infected to non-infected humans also takes place via sand fly vectors but is a significant factor for only a few *Leishmania* species (Lipoldova, Demant, 2006). Substantial rates

\*Correspondence: S. N. A. Bukhari. Department of Pharmaceutical Chemistry. College of Pharmacy. Jouf University. Sakaka, Aljouf 2014, Saudi Arabia. Phone: +966 565738896. Email: sbukhari@ju.edu.sa;snab\_hussaini@yahoo.com

of morbidity and mortality around the world are caused by leishmaniasis, and it affects many tropical and subtropical countries, including most Mediterranean nations, putting around 350 million humans at infection risk. The total occurrence of leishmaniasis is assessed to be 12 million cases around the globe, and the worldwide annual occurrence of all clinical forms of disease is 1.3 million (WHO Report, 2017). The latest refugee crisis and conflicts in North Africa and Middle East resulted in a very serious leishmaniasis outbreak (Du *et al.*, 2016). Global warming and this outbreak are the key reasons behind the increasing spread of leishmaniasis to Europe (Hotez, 2016; Naucke *et al.*, 2008) and to North America (Gonzalez *et al.*, 2010). Yet, this disease also remains neglected and current treatment options are insufficient, undermining any efforts to contain its further spread. Although research is focussing on potential drug targets in *Leishmania* and *Trypanosoma* species, and the causes of drug resistance, an effective, safer and simple substitute therapy is immediately needed.

Based on our previous results (Alkhalidi *et al.*, 2015; Changtam *et al.*, 2010; Zha *et al.*, 2016), we have endeavoured to discover new compounds with anti-protozoal activities and in doing so we have extended our earlier reported work (Zha *et al.*, 2017) comprising 34 novel  $\alpha,\beta$ -Unsaturated carbonyl-based compounds linked to ligustrazine (tetramethylpyrazine (TMP)). TMP is an important constituent of Chinese traditional medicinal plant chuanxiong (*Ligusticum chuanxiong Hort*). In this study, a series of novel  $\alpha,\beta$ -Unsaturated carbonyl-based compounds coupled to one or two TMP moieties was evaluated for their activity against a number of *Leishmania* and *Trypanosoma* strains including the well-characterised multi-drug resistant *Trypanosoma brucei* clonal line B48. This clonal line B48 is extremely resistant to the two major classes of trypanocides, the diamidines and the melaminophenyl arsenicals, due to the loss of HAPT1 and TbAT1/P2 drug transporters (Bridges *et al.*, 2007).

## MATERIAL AND METHODS

### Material

Synthetic compounds were synthesized, characterized and reported by us previously (Zha *et al.*, 2017). Stock solutions in 100% DMSO for each compound were prepared and for the concentrations

used in assay, the calculated amount of stock solution was taken and diluted with complete medium, ensuring that the final DMSO concentration did not exceed 1% in the final conditions.

### Cell culture

#### *Trypanosoma brucei bloodstream forms (BSF) in-vitro*

In this research, two strains of the bloodstream forms of *Trypanosoma brucei* were utilised. The first was the wild-type strain of *Trypanosoma brucei brucei* (s427-WT) and the other was TbAT1-B48 that was acquired from the clone TbAT1-KO, itself derived from s427WT by deletion of the *TbAT1* gene (Matovu *et al.*, 2003), by exposure to pentamidine thus causing more resistance to pentamidine, diminazene and the melaminophenyl arsenicals. Consequently, these cells have neither TbAT1/P2 transporter nor the high affinity-pentamidine transporter genes (Bridges *et al.*, 2007; Munday *et al.*, 2014). Both strains were cultured in HMI-9 medium (pH 7.4) supplemented with 10% heat-inactivated Fetal Calf Serum (FCS, BioSera) and 14  $\mu\text{L/L}$  of 13.4 M  $\beta$ -mercaptoethanol (Sigma), as described by Hirumi and Hirumi (Hirumi, Hirumi, 1989). The medium was sterilized by filtration (0.22  $\mu\text{m}$ , Millipore) inside a flow cabinet. The *T. b. brucei* cultures were incubated at 37 °C and 5% CO<sub>2</sub> and passaged in vented flasks three times a week.

#### *Leishmania major* and *Leishmania mexicana promastigotes*

*Leishmania major* strain Friedlin (LmjF) and strains of *Leishmania mexicana* (MNYC/BZ/62/M379) were propagated in essential medium (HOMEM) with a pH value of 7.4 and 10% FCS in plastic flasks, at a temperature of 25 °C. The cultures were passed to fresh medium three times per week.

#### Alamar blue assay to determine the sensitivity to test compounds

Resazurin sodium salt (Alamar Blue) is commonly used as a cell metabolic function indicator. It is a non-fluorescent, blue dye that is mixed with cell cultures containing various drug concentrations, in order to determine the sensitivity of African trypanosomes or

*Leishmania* cultures to the test compounds *in vitro* (Fumarola *et al.*, 2004; Raz *et al.*, 1997). In case there are no toxic effects caused by the drug, the color of the living cells changes from blue to red and fluorescent. Preparation of Alamar Blue involves the dissolution of 12.5 milligrams of Resazurin sodium salt (Sigma) in 100 mL of phosphate-buffered saline (PBS) of pH 7.4, which is then filter-sterilized and stored in the dark at 4 °C.

#### **Drug sensitivity using Alamar Blue assay in *T. b. brucei* BSF**

For each test compound a solution of 200 µM in HMI-9 medium + 10% FCS is prepared using a 20 mM stock solution in DMSO; 200 µL of this is added to a first well of a 96-well plate. Of this, 100 µL is transferred to the next well, containing 100 µL of the same medium, achieving a 1:1 dilution, initiating a doubling dilution series across 2 rows of the plate; each experiment was positively controlled using pentamidine and the final well for each compound received 100 microliters of HMI-9 medium as negative, drug-free control. To each well, 100 µL of a suspension of  $2 \times 10^5$  cells/mL is added, amounting to  $1 \times 10^5$  cells/mL as the final cell density. The plate is then incubated for 48 hours at 37 °C/5% CO<sub>2</sub> after which 20 µL of the Alamar Blue solution is added, followed by another incubation of the plate for 24 hours. A fluorimeter (FluoStar Optima) is used to read the fluorescence of the plate at the wavelengths of 590 nm for emission and 530 nm for excitation and the data are analysed using the GraphPad Prism 5 software package, fitting the fluorescence to a sigmoid curve with variable slope to determine the EC<sub>50</sub> value. A very similar protocol was followed using *Leishmania* promastigotes, as described (Al-Salabi *et al.*, 2003).

#### **Cytotoxicity assay on Human Foreskin Fibroblast (HFF)**

Toxicity of test compounds to mammalian cells was carried out using the resazurin assay previously described (Ebiloma *et al.*, 2018) with slight modifications. HFF human cells were grown in a culture medium containing 500 mL of Dulbecco's Modified Eagle's Medium (DMEM) (Sigma), 50 mL New-Born Calf Serum (NBCS) (Gibco), 5 mL Penicillin/Streptomycin (Gibco), and 5 mL of L-Glutamax (200 nM, Gibco). Mammalian cells were incubated at 37 °C and 5% CO<sub>2</sub> and were passaged when they reached 80-85% of confluence in vented flasks. For the cytotoxicity assay cells were suspended at  $3 \times 10^5$  cell/mL and 100 µL was added to each well of a 96-well plate. The plate was incubated at 37 °C and 5% CO<sub>2</sub> for 24 hours to allow cell adhesion. Serial test compounds dilution was performed in a different 96-well plate and 100 µL was transferred to each well containing cells. Pentamidine was used as positive control. The plates were incubated at 37 °C and 5% CO<sub>2</sub> for an additional 30 hours before 10 µL of resazurin solution (125 mg/mL in PBS) was added to each well, followed by a final incubation at 37 °C and 5% CO<sub>2</sub> for 24 hours. The plates were read using a FLUOstar Optima (BMG Labtech, Durham, NC, USA) at wavelength of 540 nm for the excitation, 590 nm for the emission. EC<sub>50</sub> values were calculated by non-linear regression using an equation for a sigmoidal dose-response curve with variable slope using Prism 5.0 (GraphPad Software Inc., San Diego, CA, USA).

## **RESULTS AND DISCUSSION**

In the present study, we demonstrated the effect of synthetic compounds (Table I) on the growth of promastigotes of *L. major*, *L. mexicana* and different strains of *Trypanosoma brucei brucei in vitro*. The antitrypanosomal and leishmanicidal activities of compounds are summarized in Table II.



**TABLE I** – Structures of tested synthetic  $\alpha$ ,  $\beta$ -Unsaturated carbonyl based compounds (Zha et al., 2017)

6g	CHCH(CH <sub>3</sub> ) <sub>2</sub>	H	H	Cl
6 h	CHCH(CH <sub>3</sub> ) <sub>2</sub>	H	OCH <sub>3</sub>	Cl
6i	CHCH(CH <sub>3</sub> ) <sub>2</sub>	OCH <sub>3</sub>	OCH <sub>3</sub>	Br
6j	NH	H	H	Cl
6k	NH	H	OCH <sub>3</sub>	Cl
6l	NH	OCH <sub>3</sub>	OCH <sub>3</sub>	Br
6m	N—CH <sub>3</sub>	H	H	Cl
6n	N—CH <sub>3</sub>	H	OCH <sub>3</sub>	Cl
6o/8o	N—CH <sub>3</sub>	OCH <sub>3</sub>	OCH <sub>3</sub>	Br
6p	NCH(CH <sub>3</sub> ) <sub>2</sub>	H	H	Cl
6q	NCH(CH <sub>3</sub> ) <sub>2</sub>	H	OCH <sub>3</sub>	Cl
6r/8r	NCH(CH <sub>3</sub> ) <sub>2</sub>	OCH <sub>3</sub>	OCH <sub>3</sub>	Br
6s	O	H	H	Cl
6t	O	H	OCH <sub>3</sub>	Cl
6u	O	OCH <sub>3</sub>	OCH <sub>3</sub>	Br

**TABLE II** – Effect of synthetic compounds on *Trypanosoma brucei brucei* and *Leishmania Mexicana* strains

No.	Compounds	<i>Trypanosoma brucei brucei</i> EC <sub>50</sub> $\mu$ M		<i>Leishmania promastigotes</i> EC <sub>50</sub> $\mu$ M	
		(WT)	(B48)	<i>L. major</i>	<i>L. mexicana</i>
1.	5a	>100	>100	>100	>100
2.	5b	30.7 $\pm$ 1.2	31.5 $\pm$ 0.3	>100	>100
3.	5c	>100	>100	>100	>100

(continuing)

**TABLE II** – Effect of synthetic compounds on *Trypanosoma brucei brucei* and *Leishmania Mexicana* strains

No.	Compounds	<i>Trypanosoma brucei brucei</i> EC <sub>50</sub> μM		<i>Leishmania promastigotes</i> EC <sub>50</sub> μM	
		(WT)	(B48)	<i>L. major</i>	<i>L. mexicana</i>
4.	5d	14.2±0.4	14.8±1.4	>100	>100
5.	5e	61.0±1.2	56.3±1.3	>100	>100
6.	5f	11.2±2.9	8.0±0.8	46.6±2.1	42.8±1.5
7.	5g	>100	>100	>100	>100
8.	6a	>100	>100	>100	>100
9.	6b	>100	>100	>100	>100
10.	6c	>100	>100	>100	>100
11.	6d	>100	>100	>100	>100
12.	6e	74.8±8.0	74.4±5.4	>100	>100
13.	6f	16.4±1.3	19.2±2.8	>100	>100
14.	6g	82.3±3.7	86.8±0.5	>100	89.3±3.0
15.	6 h	>100	>100	>100	>100
16.	6i	32.5±2.8	34.9±4.6	75.7±6.9	90.9±4.9
17.	6j	>100	>100	>100	>100
18.	6k	>100	>100	>100	>100
19.	6l	>100	>100	>100	>100
20.	6m	61.4±4.0	61.7±1.4	>100	>100
21.	6n	>100	>100	>100	>100
22.	6o	>100	>100	>100	>100
23.	6p	>100	>100	>100	>100
24.	6q	>100	>100	>100	>100
25.	6r	>100	>100	>100	>100
26.	6s	>100	>100	49.1±4.6	73.9±2.8

(continuing)

**TABLE II** – Effect of synthetic compounds on *Trypanosoma brucei brucei* and *Leishmania Mexicana* strains

No.	Compounds	<i>Trypanosoma brucei brucei</i> EC <sub>50</sub> μM		<i>Leishmania promastigotes</i> EC <sub>50</sub> μM	
		(WT)	(B48)	<i>L. major</i>	<i>L. mexicana</i>
27.	6t	54.7±2.4	61.8±1.4	>100	>100
28.	6u	>100	>100	>100	>100
29.	7b	>100	>100	>100	>100
30.	7e	>100	>100	>100	>100
31.	7f	>100	>100	>100	>100
32.	8f	54.9±1.6	56.1±2.2	>100	>100
33.	8o	7.2±0.3	6.9±0.0	>100	>100
34.	8r	>100	>100	>100	>100
	Pentamidine	0.005±0.00	0.37±0.01	4.3±0.2	1.2±0.1


All EC<sub>50</sub> values were obtained using the Alamar blue assay and are given as averages in μM (±SEM), of 3 independent evaluations. WT = wild-type sensitive control strain; B48 is a multi-drug resistant clone; Resistance Factor = EC<sub>50</sub> (resistant clone)/EC<sub>50</sub> (WT).

### Antitrypanosomal activity of synthetic compounds

All 34 synthetic α,β-Unsaturated carbonyl-based compounds and their oxime derivatives were assessed for *in vitro* trypanocidal properties on two different types of *Trypanosoma brucei brucei* including wild type (WT) and the highly resistant *Trypanosoma brucei* clonal line B48 (Table II). Twelve compounds inhibited both strains, with almost identical EC<sub>50</sub> values. The highest inhibitory activity was exhibited by oxime derivative **8o** (EC<sub>50</sub> = 6.9 μM) for clonal line B48 and second most strong inhibitor was cyclohexanone derivative **5f** with EC<sub>50</sub> = 8.0 μM.

All compounds bear a central cyclohexanone linker that was substituted with seven different types of functional groups. On both sides of central linker

aldehydes were attached through an unsaturated bond. These compounds can be divided in two main groups on the basis of their chemical backbones for detailed explanation of their biological activities. The first group contains α,β-Unsaturated carbonyl-based cyclohexanone compounds (**5a-g**) and (**6a-u**). While the other group contains oximes (**7b,e,f**) and (**8f,o,r**) that were synthesized from α,β-Unsaturated carbonyl-based compounds. This first group of cyclohexanone derivatives can also be further subdivided in two classes as compounds **5a-g** contain a tetramethylpyrazine (TMP) moiety on both sides of the central cyclohexanone linker while **6a-u** contain TMP on only one side of the linker and a different type of substituted aldehyde on the other side (see scheme 1).



**Scheme 1** – Synthesis scheme of  $\alpha, \beta$ -Unsaturated carbonyl based compounds, oxime and oxime ether analogs. Reagents and conditions: (i-a) 30%  $H_2O_2$ , acetic acid, 70 °C, 8 h.; (i-b) acetic anhydride, reflux, 2 h; (i-c) 20% NaOH; (ii) IBX, DMSO, room temperature, 0.5 h; (iii) NaOH, EtOH, Room temperature (iv)  $NH_2OH \cdot HCl$ , pyridine, ethanol, anhyd., reflux (Zha et al., 2017).

In comparison of trypanocidal properties (Table II) of tested compounds it was observed that the first class of cyclohexanone derivatives (**5a-g**), containing a tetramethylpyrazine (TMP) moiety on both sides of central cyclohexanone linker, were more active than respective oximes (**7b,e,f**). As (**5b, d, e** and **f**) showed inhibition of *Trypanosoma brucei brucei* including wild type (WT) and the highly resistant *Trypanosoma brucei* clonal line B48 with  $EC_{50}$  ranging from 11.2 to 61.0  $\mu M$  but respective

oximes (**7b,e,f**) displayed  $EC_{50}$  above 100  $\mu M$  and should be considered inactive against *T. brucei*. On the other hand, one oxime **8o** was found to be a strong inhibitor for both strains although its carbonyl precursor **6o** was completely inactive. It was also interesting observation that oximes were found active while they have TMP moiety on only one side of central cyclohexanone linker. These variations showed that central linkers and substitutions on the both sides of aromatic rings played a vital role in the biological

properties of these compounds and different combinations of cyclohexanone substitutions and functional groups on aldehyde rings exhibited different patterns of trypanocidal properties. Compound **8o** was the most active against *Trypanosoma brucei* but its carba-isoster, compound **8f** was around 7 times less potent, so clearly the basic nitrogen seems important for activity. Curiously though, compounds **6m**, **6n** and **6o**, all bearing the same R1 group as **8o**, were not active at all, suggesting that the oxime is even more important than the basic Nitrogen. And, to make everything more interesting and complex, compound **8r**, was inactive, despite having a basic nitrogen and the oxime group. The result with **8r** made clear that there is a size limit for the alkyl group bonded to the basic nitrogen. All this seem to change in the symmetric series of compounds **5a-g**, where **5f** was the most active, bearing the bulkier substituent at the basic nitrogen.

All compounds showed similar effects on *Trypanosoma brucei* wild type and B48, which is a multi-drug resistant line with *in vitro* resistance to pentamidine, proving that there is no cross-resistance between this TMP/cyclohexanone/cyclohexoxime scaffold and the most important classes of trypanocides currently in clinical use. Indeed, in our previous study we reported on an extensive series of curcumin-related  $\alpha,\beta$ -Unsaturated carbonyl-based compounds with various chemical modifications to the corresponding demethylated, methylated and higher alkylated analogs (Changtam *et al.*, 2010) and the result with the B48 line was unexpected, as this line displayed hypersensitivity to some of the most promising curcuminoids (Changtam *et al.*, 2010).

### Antileishmanial activity of synthetic compounds

The same 34 synthetic  $\alpha,\beta$ -Unsaturated carbonyl-based compounds and their oxime derivatives were tested on promastigotes of *L. major* and *L. mexicana* (Table II). Only three new compounds (**5f**, **6i** and **6s**) showed any inhibition, with  $EC_{50}$  values in the range 46.6 to 75.6  $\mu$ M for *L. major*. The same three compounds, in addition to compound **6g**, exhibited some inhibition of *L. mexicana*. However, the activity was generally below that displayed for *Trypanosoma brucei brucei*. In fact, we found only weak correlation between the trypanocidal and antileishmanial activity of these compounds, with **8o** displaying no activity at all against either species of *Leishmania*, and **6s** having no effect against *T. brucei* at 100  $\mu$ M. The fact that **5f** was active against both

*Trypanosoma* and *Leishmania* indicates that maybe it has a molecular target that is common to both parasites, or at least is the same kind of receptor or enzyme. Therefore at least some of the compounds appear to act on a highly species-specific target, explaining the absence of activity against human cell lines (see below).

### Effect of synthetic ligustrazine-based compounds on a human cell line

To assess whether the antiprotozoal activity depicted for tested compounds should be attributed to general toxicity, rather than specific antiprotozoal activity, some of the most active analogs (**5d**, **6f** and **8o**) were also tested for their effect on human foreskin fibroblast (HFF) cells. The toxicity to HFF cells was very low and the selected test compounds exhibited high  $EC_{50}$  values. The highest concentration tested on HFF (human cells) was 300  $\mu$ M. Cyclohexanone derivatives **5d** and **6f** showed the value  $> 300 \mu$ M and oxime derivative **8o** showed the  $EC_{50}$  value  $280.6 \pm 8.05 \mu$ M that was also very high. Phenylarsine oxide (PAO or PhAsO), an organometallic compound, was used as control and it was found to be strongly toxic with  $EC_{50} = 1.17 \pm 0.12 \mu$ M.

### CONCLUSION

In this study some synthetic cyclohexanone and oxime derivatives have been identified with potential applications against trypanosomiasis and leishmaniasis, based on their sturdy antiparasitic activity and low toxicity. The results obtained herein revealed that some compounds including **5f** and **8o** can be effective against trypanosomiasis as they showed effects on both tested strains and they can serve as starting points for structure-based lead optimization and development against *T. brucei*.

### CONFLICTS OF INTEREST

The authors declare no conflict of interests.

### REFERENCES

Al-Salabi MI, Wallace LJM, de Koning HP. A Leishmania major nucleobase transporter responsible for allopurinol uptake is a functional homolog of the *Trypanosoma brucei* H<sub>2</sub> transporter. Mol Pharmacology. 2003;63(4):814-820. DOI: 10.1124/mol.63.4.814.

- Alkhalidi AA, Creek DJ, Ibrahim H, Kim DH, Quashie NB, Burgess KE, Changtam C, Barrett MP, Suksamrarn A, de Koning HP. Potent trypanocidal curcumin analogs bearing a monoenone linker motif act on *Trypanosoma brucei* by forming an adduct with trypanothione. *Mol Pharmacol.* 2015;87(3):451-64. DOI: 10.1124/mol.114.096016.
- Barrett MP. Problems for the chemotherapy of human African trypanosomiasis. *Curr Opin Infect Dis.* 2000;13(6):647-651.
- Barrett MP, Burchmore RJ, Stich A, Lazzari JO, Frasch AC, Cazzulo JJ, Krishna S. The trypanosomiasis. *Lancet.* 2003;362(9394):1469-80. DOI: 10.1016/s0140-6736(03)14694-6.
- Bisser S, Ouwe-Missi-Oukem-Boyer ON, Toure FS, Taoufiq Z, Bouteille B, Buguet A, Mazier D. Harboring in the brain: A focus on immune evasion mechanisms and their deleterious effects in malaria and human African trypanosomiasis. *Int J Parasitol.* 2006;36(5):529-40. DOI: 10.1016/j.ijpara.2006.02.001.
- Blum J, Schmid C, Burri C. Clinical aspects of 2541 patients with second stage human African trypanosomiasis. *Acta Trop.* 2006;97(1):55-64. DOI: 10.1016/j.actatropica.2005.08.001.
- Bridges DJ, Gould MK, Nerima B, Maser P, Burchmore RJ, de Koning HP. Loss of the high-affinity pentamidine transporter is responsible for high levels of cross-resistance between arsenical and diamidine drugs in African trypanosomes. *Mol Pharmacol.* 2007;71(4):1098-108. DOI: 10.1124/mol.106.031351.
- Büscher P, Cecchi G, Jamonneau V, Priotto G. Human African trypanosomiasis. *The Lancet.* 2017;390(10110):2397-2409. DOI: 10.1016/S0140-6736(17)31510-6.
- Changtam C, de Koning HP, Ibrahim H, Sajid MS, Gould MK, Suksamrarn A. Curcuminoid analogs with potent activity against *Trypanosoma* and *Leishmania* species. *Eur J Med Chem.* 2010;45(3):941-56. DOI: 10.1016/j.ejmech.2009.11.035.
- Du R, Hotez PJ, Al-Salem WS, Acosta-Serrano A. Old World Cutaneous Leishmaniasis and refugee crises in the Middle East and North Africa. *PLoS Neglected Tropical Diseases.* 2016;10:e0004545. DOI: 10.1371/journal.pntd.0004545.
- Ebiloma GU, Ayuga TD, Balogun EO, Gil LA, Donachie A, Kaiser M, Herraiz T, Inaoka DK, Shiba T, Harada S, Kita K, de Koning HP, Dardonville C. Inhibition of trypanosome alternative oxidase without its N-terminal mitochondrial targeting signal ( $\Delta$ MTS-TAO) by cationic and non-cationic 4-hydroxybenzoate and 4-alkoxybenzaldehyde derivatives active against *T. brucei* and *T. congolense*. *Eur J Med Chem.* 2018;150:385-402. DOI: 10.1016/j.ejmech.2018.02.075.
- Fumarola L, Spinelli R, Brandonisio O. In vitro assays for evaluation of drug activity against *Leishmania* spp. *Res Microbiol.* 2004;155(4):224-30. DOI: 10.1016/j.resmic.2004.01.001.
- Gonzalez C, Wang O, Strutz SE, Gonzalez-Salazar C, Sanchez-Cordero V, Sarkar S. Climate change and risk of leishmaniasis in north america: predictions from ecological niche models of vector and reservoir species. *PLoS Negl Trop Dis.* 2010;4(1):e585. DOI: 10.1371/journal.pntd.0000585.
- Hirumi H, Hirumi K. Continuous cultivation of *Trypanosoma brucei* blood stream forms in a medium containing a low concentration of serum protein without feeder cell layers. *J Parasitol.* 1989;75(6):985-9.
- Hotez PJ. Southern Europe's Coming Plagues: Vector-Borne Neglected Tropical Diseases. *PLoS Neglected Tropical Diseases.* 2016;10(6):e0004243. DOI: 10.1371/journal.pntd.0004243.
- La Greca F, Magez S. Vaccination against trypanosomiasis: can it be done or is the trypanosome truly the ultimate immune destroyer and escape artist? *Hum Vaccin.* 2011;7(11):1225-33. DOI: 10.4161/hv.7.11.18203.
- Lipoldova M, Demant P. Genetic susceptibility to infectious disease: lessons from mouse models of leishmaniasis. *Nat Rev Genet.* 2006;7(4):294-305. DOI: 10.1038/nrg1832.
- Matovu E, Stewart ML, Geiser F, Brun R, Maser P, Wallace LJ, Burchmore RJ, Enyaru JC, Barrett MP, Kaminsky R, Seebeck T, de Koning HP. Mechanisms of arsenical and diamidine uptake and resistance in *Trypanosoma brucei*. *Eukaryot Cell.* 2003;2(5):1003-8.
- Munday JC, Eze AA, Baker N, Glover L, Clucas C, Aguinaga Andres D, Natto MJ, Tekka IA, McDonald J, Lee RS, Graf FE, Ludin P, Burchmore RJ, Turner CM, Tait A, MacLeod A, Maser P, Barrett MP, Horn D, De Koning HP. *Trypanosoma brucei* aquaglyceroporin 2 is a high-affinity transporter for pentamidine and melaminophenyl arsenic drugs and the main genetic determinant of resistance to these drugs. *J Antimicrob Chemother.* 2014;69(3):651-63. DOI: 10.1093/jac/dkt442.
- Naucke TJ, Menn B, Massberg D, Lorentz S. Sandflies and leishmaniasis in Germany. *Parasitol Res.* 2008;103(Suppl 1):S65-8. DOI: 10.1007/s00436-008-1052-y.
- Olliaro P, Lazdins J, Guhl F. Developments in the treatment of leishmaniasis and trypanosomiasis. *Expert Opinion on Emerging Drugs.* 2002;7(1):61-67. DOI: 10.1517/14728214.7.1.61.
- Raz B, Iten M, Grether-Buhler Y, Kaminsky R, Brun R. The Alamar Blue assay to determine drug sensitivity of African

trypanosomes (*T.b. rhodesiense* and *T.b. gambiense*) in vitro. *Acta Trop.* 1997;68(2):139-47.

WHO Report. Leishmaniasis. 2017. Fact sheet N°375: Updated April 2017.

WHO Report. Investing to Overcome the Global Impact of Neglected Tropical Diseases. Geneva, Switzerland. 2015; [http://apps.who.int/iris/bitstream/10665/152781/1/9789241564861\\_eng.pdf?ua=1](http://apps.who.int/iris/bitstream/10665/152781/1/9789241564861_eng.pdf?ua=1) (accessed 26 February 2015).

Zha GF, Qin HL, Youssif BGM, Amjad MW, Raja MAG, Abdelazeem AH, Bukhari SNA. Discovery of potential anticancer multi-targeted ligustrazine based cyclohexanone and oxime analogs overcoming the cancer multidrug

resistance. *Eur J Med Chem.* 2017;135:34-48. DOI: 10.1016/j.ejmech.2017.04.025.

Zha GF, Zhang CP, Qin HL, Jantan I, Sher M, Amjad MW, Hussain MA, Hussain Z, Bukhari SN. Biological evaluation of synthetic alpha,beta-unsaturated carbonyl based cyclohexanone derivatives as neuroprotective novel inhibitors of acetylcholinesterase, butyrylcholinesterase and amyloid-beta aggregation. *Bioorg Med Chem.* 2016;24(10):2352-9. DOI: 10.1016/j.bmc.2016.04.015.

Received for publication on 15<sup>th</sup> December 2018

Accepted for publication on 05<sup>th</sup> August 2019